Bristol Myers Squibb Company
BMYHealthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.78%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
Follow BMY
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 13.2% in Q3 FY26, against a low of 11.0% in Q4 FY25. ROE, at 44.0%, is far above it because equity is small against the capital the business uses.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 40.4% | 38.8% | 46.6% | 44.0% |
| ROIC | 11.0% | 11.1% | 13.7% | 13.2% |
Debt
Net debt is 9.58× a year’s EBITDA. Debt is 1.83× equity, against 2.44× in Q4 FY25.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Debt / equity | 2.4× | 2.2× | 1.9× | 1.8× |
| Net debt / EBITDA | 14.1× | 8.9× | 6.8× | 9.6× |
Cash cycle, in days
Customers pay in 78 days, inventory is held 64 days and suppliers are paid in 110. Cash is tied up for 32 days between paying for goods and being paid.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Cash cycle | 63 | 33 | 43 | 32 |
| Days to pay suppliers | 94 | 108 | 103 | 110 |
| Days to be paid | 86 | 71 | 78 | 78 |
Per share, from Q4 FY25
Since Q4 FY25, per share: free cash flow has fallen 28.0%; revenue has grown 3.36%; book value has grown 25.9%.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Free cash flow | 1.0× | 0.9× | 0.9× | 0.7× |
| Revenue | 1.0× | 1.0× | 1.0× | 1.0× |
| Book value | 1.0× | 1.1× | 1.2× | 1.3× |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 44.01% | 46.63% | 38.75% | 40.43% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
7 | 7 | 7 | 8 | |
| 9.96% | 10.18% | 8.13% | 7.72% | ||
ROIC |
13.19% | 13.69% | 11.09% | 11.01% | |
Return on Tangible Assets |
48.69% | 52.41% | 46.31% | 52.19% | |
Average Days of Receivables |
77.61 | 78.31 | 70.53 | 86.44 | |
Free Cash Flow per Share |
4.55 | 5.60 | 5.84 | 6.32 | |
Free Cash Flow |
9,286.00 | 11,440.00 | 11,908.00 | 12,845.00 | |
Capital Expenditures |
(1,366.00) | (1,342.00) | (1,398.00) | (1,311.00) | |
| Other line items | |||||
Cash ROIC |
11.77% | 14.95% | 15.87% | 17.29% | |
Accounts Receivable Turnover |
4.54 | 4.48 | 4.81 | 4.35 | |
Accounts Payable Turnover |
3.45 | 3.06 | 3.48 | 3.88 | |
Inventory Turnover |
5.63 | 5.36 | 5.28 | 5.31 | |
Average Days of Payables |
109.77 | 103.40 | 107.89 | 93.63 | |
Days of Inventory on Hand |
64.13 | 68.06 | 70.23 | 70.45 | |
Tax Rate |
(0.18) | (0.22) | (0.24) | (0.24) | |
Research and Development Expense of Revenue |
21.10% | 21.80% | 21.33% | 20.65% | |
Selling, General and Administrative Expense of Revenue |
14.64% | 15.07% | 15.06% | 15.08% | |
Share Based Compensation of Revenue |
1.10% | 1.12% | 1.14% | 1.15% | |
Operating CF/Net income |
1.15 | 1.38 | 1.83 | 2.01 | |
Depreciation/Fixed assets |
0.35 | 0.41 | 0.47 | 0.53 | |
Capex/Depreciation |
(0.49) | (0.42) | (0.39) | (0.33) | |
Revenue per Share |
24.49 | 24.09 | 23.79 | 23.69 | |
Operating CF per Share |
5.21 | 6.26 | 6.53 | 6.96 | |
Capex per Share |
(0.67) | (0.66) | (0.69) | (0.64) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 |